Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Rhea-AI Summary
Oncolytics Biotech (Nasdaq: ONCY) reported initial preclinical data showing pelareorep combined with RAS inhibitor modalities achieved greater anti-tumor activity than either approach alone in a solid tumor model.
The company plans further studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), with full results expected in late 2026.
Positive
- Preclinical combo shows greater anti-tumor activity than individual approaches
- Planned additional PDAC and CRC preclinical studies of pelareorep combinations
- Ongoing work includes KRAS G12C, pan-RAS and next-generation RAS agents
- Strategy targets RAS-mutated tumors with limited current treatment options
- Full initial preclinical dataset planned for presentation in late 2026
Negative
- Findings are early preclinical data, not clinical outcomes
- Full preclinical results not expected until fall or winter 2026
News Market Reaction – ONCY
In the Jun 1 session, ONCY gained 1.92%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.5% during that session. Argus tracked a trough of -20.2% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Strategy commentary | Positive | +0.1% | CEO interview stressing pelareorep as immune‑priming backbone with strong survival signals. |
| May 22 | Conference data | Positive | +2.5% | ASCO 2026 translational data on pelareorep across gastrointestinal and breast tumors. |
| May 04 | Clinical data update | Positive | +6.6% | REO 022 colorectal cancer data showing long response duration and solid objective response rate. |
| Apr 27 | Regulatory alignment | Positive | -6.0% | FDA alignment on pivotal anal cancer study design targeting accelerated and full approval. |
| Apr 06 | Regulatory meeting plan | Positive | -1.1% | Planned Type C FDA meeting to discuss single‑arm registrational anal cancer pathway. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent oncology and regulatory milestones have often led to positive reactions, but there are notable instances where favorable FDA-alignment news coincided with short-term price declines.
Over the last two months, ONCY has repeatedly highlighted pelareorep’s role in difficult-to-treat cancers. Positive colorectal and anal cancer data on May 4 and FDA alignment for a pivotal anal cancer trial on April 27 underscored durable responses and survival benefits. Additional ASCO 2026 presentations and an in-depth CEO interview further framed pelareorep as an immune‑priming backbone. Today’s preclinical RAS-combination findings extend this narrative into RAS‑mutated tumors, consistent with the company’s focus on combination strategies and durability endpoints.
Key Terms
immunotherapy medical
cytokines medical
tertiary lymphoid structures medical
tumor-infiltrating lymphocytes medical
pancreatic ductal adenocarcinoma medical
KRAS G12C inhibitors medical
pan-RAS inhibitors medical
RAS-mutated medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.
Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma (“PDAC”) and colorectal cancer (“CRC”) designed to further evaluate the combinations’ effects on immune activation, tumor response durability, and time-to-resistance. The ongoing work includes evaluations of pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and additional next-generation RAS pathway-targeting agents in RAS-mutated tumor models.
“We believe these initial findings further support pelareorep’s potential to serve as an immune-priming backbone for next-generation targeted therapies,” said Jared Kelly, Chief Executive Officer of Oncolytics. “RAS-mutated tumors, particularly pancreatic and colorectal cancers, remain among the most difficult cancers to treat due to intrinsic immune resistance and the emergence of therapeutic resistance over time. These preclinical results support further study of the combinations’ anti-tumor and immune effects, including in models designed to assess durability and time-to-resistance.”
Mr. Kelly continued, “Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options. The potential synergy observed in previous PDAC clinical studies and preclinical RAS-targeted modalities reinforces our belief that pelareorep may play an important role in future combination strategies designed to improve the durability of targeted therapies.”
Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors to “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies, its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
